Country-based report: the safety of omalizumab treatment in pregnant patients with asthma

BACKGROUND/AIM: We aimed to report outcomes of pregnant patients with asthma under omalizumab treatment and their infants in our country. MATERIALS AND METHODS: Patients with asthma who received omalizumab for at least 6 months and at least one dose during their pregnancy were retrospectively evalua...

Descripción completa

Detalles Bibliográficos
Autores principales: GEMİCİOĞLU, Bilun, YALÇIN, Arzu Didem, HAVLUCU, Yavuz, KARAKAYA, Gül, ÖZDEMİR, Levent, KEREN, Metin, BAVBEK, Sevim, EDİGER, Dane, OĞUZÜLGEN, İpek Kıvılcım, ÖZŞEKER, Zeynep Ferhan, YORGANCIOĞLU, Arzu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Scientific and Technological Research Council of Turkey 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8742481/
https://www.ncbi.nlm.nih.gov/pubmed/34174791
http://dx.doi.org/10.3906/sag-2101-341

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8742481/
https://www.ncbi.nlm.nih.gov/pubmed/34174791
http://dx.doi.org/10.3906/sag-2101-341

Ejemplares similares